系统性红斑狼疮新药研发的当前挑战
本文综述了系统性红斑狼疮(SLE)临床试验的成就与主要陷阱,指出尽管试验众多但仅一个新药获批,强调需在入组标准、结局指标和试验设计上达成共识以推进研发。
要点
- SLE临床试验众多但仅一个新药获批,整体研发速度缓慢。
- 大量试验深化了对入组标准、结局指标和试验设计的理解。
- 需通过合作与共识解决SLE药物研发中的关键问题。
核心结论
- SLE新药研发虽试验众多但成功缓慢,仅一个新药获批,需在入组标准、结局指标和试验设计上加强合作与共识。
研究设计与样本
- 本文为综述,基于对SLE临床试验的回顾性分析,未报告系统检索范围。
主要发现
- 自世纪之交以来SLE临床试验众多,但仅一个新治疗获批,整体研发速度仍慢。
- 大量临床研究提供了对入组标准、结局指标和试验设计的深入认识。
临床怎么用
- 临床医生应关注SLE试验设计中的入组标准与结局指标演变,以理解新药研发的挑战。
局限性
- 本文为综述,未报告系统检索策略或纳入研究的详细方法学质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a considerable impact on patients' quality of life. Despite the plethora of clinical trials for SLE since the turn of the millennium, only one new treatment has been approved for the condition, and the overall pace of successful drug development remains slow. Nevertheless, the myriad of clinical studies has yielded insights that have informed and refined our understanding of eligibility criteria, outcome measures and trial design in SLE. In this review, we highlight the achievements of clinical trials as well as the major pitfalls that have been identified in drug development for SLE and, in doing so, identify areas where collaboration and consensus will be important to facilitate progress.
引用
- Dall'Era M, Bruce IN, Gordon C, et al. Current challenges in the development of new treatments for lupus. Ann Rheum Dis. 2019. PMID: 30636212. doi:10.1136/annrheumdis-2018-214530
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。